{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:28:23Z","timestamp":1792985303978,"version":"4.5.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union FP7-HEALTH","award":["HEALTH-F3\u20132009\u2013242135"],"award-info":[{"award-number":["HEALTH-F3\u20132009\u2013242135"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0198478","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T13:27:17Z","timestamp":1528205237000},"page":"e0198478","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides"],"prefix":"10.1371","volume":"13","author":[{"given":"Cristina","family":"Tintori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iovenitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Rita","family":"Ceresola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalaura","family":"Brai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dreassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Canducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-6995","authenticated-orcid":true,"given":"Maurizio","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"ref1","article-title":"Global health sector strategy on sexually transmitted infections 2016\u20132021","year":"2016"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0140-6736(10)61200-7","article-title":"After CAPRISA 004: time to re-evaluate the HIV lexicon","volume":"376","author":"W Jr Cates","year":"2010","journal-title":"Lancet"},{"key":"ref3","first-page":"490","article-title":"The North Carolina contribution to the CAPRISA 004 study: the Global Health Initiative in action","volume":"71","author":"W Jr Cates","year":"2010","journal-title":"N C Med J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1745-6215-12-67","article-title":"Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial","volume":"12","author":"QA Karim","year":"2011","journal-title":"Trials"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/infdis\/jis305","article-title":"CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck","volume":"206","author":"Z Valley-Omar","year":"2012","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1128\/JCM.03143-13","article-title":"Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial","volume":"52","author":"AD Redd","year":"2014","journal-title":"J Clin Microbiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAI.0000000000000607","article-title":"Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness","volume":"69","author":"AD Kashuba","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/QAD.0b013e328355ce08","article-title":"Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial","volume":"26","author":"A Grobler","year":"2012","journal-title":"AIDS"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s10461-014-0749-4","article-title":"Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial","volume":"18","author":"TN Gengiah","year":"2014","journal-title":"AIDS Behav"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10461-014-0751-x","article-title":"Adherence in the CAPRISA 004 tenofovir gel microbicide trial","volume":"18","author":"LE Mansoor","year":"2014","journal-title":"AIDS Behav"},{"key":"ref11","first-page":"1211","article-title":"Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis","volume":"211","author":"DA Lehman","year":"2015","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/338231","article-title":"Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis","volume":"185","author":"A Wald","year":"2002","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1086\/345867","article-title":"Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men","volume":"187","author":"C Renzi","year":"2003","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/368357","article-title":"Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India","volume":"187","author":"SJ Reynolds","year":"2003","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/OLQ.0b013e31822e60b6","article-title":"Prevalence of herpes simplex virus type 2 infection, human immunodeficiency virus\/herpes simplex virus type 2 coinfection, and associated risk factors in a national, population-based survey in Kenya","volume":"38","author":"N Mugo","year":"2011","journal-title":"Sex Transm Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/IJWH.S27601","article-title":"Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females","volume":"4","author":"D Tan","year":"2012","journal-title":"Int J Womens Health"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1021\/ci800105p","article-title":"Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery","volume":"48","author":"C Tintori","year":"2008","journal-title":"J Chem Inf Model"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cmdc.201000510","article-title":"A versatile and practical synthesis toward the development of novel HIV-1 integrase inhibitors","volume":"6","author":"M Rinaldi","year":"2011","journal-title":"ChemMedChem"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.bmcl.2017.03.097","article-title":"One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity","volume":"27","author":"L Botta","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"ref20","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"SM Woollard","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/TCRM.S2268","article-title":"Raltegravir: first in class HIV integrase inhibitor","volume":"4","author":"Z Temesgen","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1023\/A:1007537520620","article-title":"A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening","volume":"17","author":"HH Parikh","year":"2000","journal-title":"Pharm Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/17425247.2012.668183","article-title":"Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission","volume":"9","author":"DR Friend","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tim.2015.02.006","article-title":"Multipurpose prevention technologies: the future of HIV and STI protection","volume":"23","author":"JA Fernandez-Romero","year":"2015","journal-title":"Trends Microbiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425247.2016.1134485","article-title":"An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy","volume":"13","author":"DR Friend","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.contraception.2017.10.006","article-title":"Interest in multipurpose prevention technologies to prevent HIV\/STIs and unintended pregnancy among young women in the United States","volume":"97","author":"JS Hynes","year":"2018","journal-title":"Contraception"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(16)30550-3","article-title":"The promise of multipurpose pregnancy, STI, and HIV prevention","volume":"17","author":"M Quaife","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e0185946","DOI":"10.1371\/journal.pone.0185946","article-title":"Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model","volume":"12","author":"JM Smith","year":"2017","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.02739-13","article-title":"2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors","volume":"58","author":"M Tiberi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/cbic.201500385","article-title":"Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation","volume":"16","author":"F Esposito","year":"2015","journal-title":"Chembiochem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/cbic.201500668","article-title":"Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules","volume":"17","author":"C Tintori","year":"2016","journal-title":"Chembiochem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cbic.201600592","article-title":"Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding","volume":"18","author":"R Martini","year":"2017","journal-title":"Chembiochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"F Canducci","year":"2011","journal-title":"J Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/jac\/dkt220","article-title":"In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir","volume":"68","author":"F Canducci","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1472-6882-13-266","article-title":"In vitro anti-Herpes simplex virus activity of crude extract of the roots of Nauclea latifolia Smith (Rubiaceae)","volume":"13","author":"M Donalisio","year":"2013","journal-title":"BMC Complement Altern Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm001020e","article-title":"High-throughput permeability pH profile and high-throughput alkane\/water log P with artificial membranes","volume":"44","author":"F Wohnsland","year":"2001","journal-title":"J Med Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/108705710100600309","article-title":"High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay","volume":"6","author":"K Sugano","year":"2001","journal-title":"J Biomol Screen"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0198478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:37:18Z","timestamp":1588959438000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0198478"}},"subtitle":[],"editor":[{"given":"Giovanni","family":"Maga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0198478","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]}}}